

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 October 2023 (05.10.2023)



(10) International Publication Number
WO 2023/192801 A1

(51) International Patent Classification:

C07D 417/04 (2006.01) C07D 491/08 (2006.01)
C07D 417/14 (2006.01) A61P 35/00 (2006.01)
C07D 471/08 (2006.01) A61K 31/506 (2006.01)
C07D 487/08 (2006.01)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/064895

(22) International Filing Date:

24 March 2023 (24.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/362,036 28 March 2022 (28.03.2022) US

(71) Applicant: NIKANG THERAPEUTICS, INC. [US/US];

200 Powder Mill Road, Bldg. E500, Wilmington, Delaware 19803 (US).

(72) Inventor: LOU, Yan; c/o NiKang Therapeutics, Inc., 200

Powder Mill Road, Bldg. E500, Wilmington, Delaware 19803 (US).

(74) Agent: MACALPINE, Jill K. et al.; Finnegan, Henderson,

Farabow, Garrett & Dunner, LLP, 901 New York Avenue, N.W., Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,


Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS



(57) Abstract: The present disclosure provides certain sulfonamido derivatives that are Cyclin-dependent kinase 2 (CDK2) inhibitors of Formula (I); for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

WO 2023/192801 A1